Global Immuno-Oncology Market Is Ruled by APAC, Europe and North America, Says RNCOS in New Report Available at MarketPublishers.com
30 Jan 2017 • by Natalie Aster
LONDON – A large number of advancements have taken place in the immuno-oncology marketplace over the recent years. The competition between companies is becoming increasingly intense given the strong move towards launching new and the most effective therapies.
The market will grow tremendously in the upcoming years to be worth billions of US dollars.
In terms of product types, the monoclonal antibodies segment dominated the worldwide space as of 2016 given the increasing prevalence of cancer and their growing usage in many therapies. APAC, North America and Europe are leading geographies in the world’s market. In terms of applications, melanoma and lung cancer are frontrunners.
Rising cancer incidences and growth in the geriatric populations are some of major driving forces of the worldwide marketplace. Increasing sales of immune checkpoint inhibitors also encourage the growth. Still, there are some challenges like the patient expiry among top-selling drugs, a high cost of treatment and a lack of awareness, to name a few.
Amgen, Pfizer, Merc & Co and Novartis are some of top companies in the worldwide space.
New research report “Immuno-Oncology Market, By Type, Cancer Vaccines, Immune Checkpoint Inhibitors, By Application - Global Forecast to 2022” worked out by RNCOS offers a comprehensive guide to the world’s immuno-oncology marketplace. The study commences with an all-round overview of the space.
It delves very deep into the driving forces; explores challenges as well as opportunities of the global market. The report insightfully examines product classes and covers major indications.
The research study concentrates on major geographies and the performance of the marketplace there. It throws light on key trends and development in this marketplace. The report limelights strategic collaborations and alliances in the global space.
The research study analyzes the pipeline and scrutinizes the competitive environment. Details on major companies (some of them were mentioned above) and global forecasts through 2022 are on hand in the report, too.
More new reports by RNCOS can be found at its page.